What You Missed: The 2nd Annual Optimizing AAV Safety Summit 2023
The 4th Annual Gamma Delta T Therapies Summit gathered the leading therapeutic developers of cell and antibody-based approaches to bring to market efficacious, persistent, off-the-shelf Gamma Delta T Therapies for solid tumors.
The 4th Annual Gamma Delta T Therapies Summit returned to Boston in July as the hotly anticipated and world’s only industry-focused forum dedicated to building on early clinical successes, highlighting process, and engineering innovations and leveraging early clinical insights to successfully advance Gamma Delta T Therapies to the Clinic and beyond.
What You Missed:
|Unearth the mechanisms and pathways involved in Gamma Delta T Cell Cytotoxicity with the CSO of In8bio|
|Map the cell to cell and environmental interactions of Gamma Delta T cells to understand the in vivo influences with Triumvira|
|Advance novel approaches to capitalize on the potential of Gamma Delta Therapeutics beyond Oncology with Regeneron|
|Address lessons learned to take into phase 2 clinical trial design, dose escalation, patient selection, pharmacodynamics, and safety with the CSO of Adicet Bio|
|Identify patient populations with clinical rationale to align with the mechanism of action with Imcheck Therapeutics|
|Develop targets to engineer or combine therapies to enhance tumor homing and infiltration with Emory University|
|Robustly test the impact of construct design on the persistence of cells and therapeutic response with Adicet Bio|